This will be a prospective observational trial enrolling 20 patients with osseointegrated prostheses. Participants will be recruited from the orthopaedic outpatient clinic at Walter Reed National Military Medical Center in Bethesda, MD.
All eligible consenting patients will undergo daily stoma management per standard of care.
Patients will integrate antimicrobial photodynamic therapy into their stoma management program. The first treatment will take place in the orthopaedic clinic. All others will take place at home. Topical 5-ALA will be applied to the metal at the penetration site. After 2 hours, the light delivery device will be utilized and light will be administered for 15 minutes.
Data collection: After obtaining informed consent, study personnel will record injury-specific variables, surgery-specific variables, other variables related to their hospital course, demographic variables as well as comorbidities on the study case report forms (CRFs). They will obtain this information directly from the participant, from the participant's medical record, and the participant's treating orthopaedic surgeon or other health care providers. Baseline data collection points include participant characteristics and amputation details such as age, sex, comorbidities, highest education level achieved, social support, initial reason for amputation, type of amputation and all surgical dates. Study participants will be followed at 1 and 2 weeks after initiation of PDT treatment. To ensure research participant safety, serious adverse events (SAEs) will be documented and promptly submitted to the local IRB as per the required reporting processes.
Follow-up: Study participants will be followed at 1 week and 2 weeks.

开始日期2025-03-01

申办/合作机构

Dartmouth-Hitchcock Medical Center

[+1]

NCT06623201

/ Not yet recruiting临床1期IIT

Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas

This research study is testing combination Blue-light photodynamic therapy and Sonidegib as a possible treatment for people with multiple basal cell carcinoma lesions.
Basal cell carcinoma lesions are typically treated by freezing the lesion or surgically removing the lesion. These types of treatment can cause scarring. Photodynamic therapy uses light along with a drug applied to the skin to kill the cancer cells and cause them to break apart. The light used can cause the skin to feel warm, but does not cause scarring.

开始日期2024-12-01

申办/合作机构-

NCT06678867

/ Not yet recruiting临床2期IIT

A Phase II Multicentre Trial for the Use of 5-ALA Paediatric Patients with High Grade Brain Tumours

The aim of the study is to examine the safety and feasibility of using 5-ALA in children who have MRI scans showing an aggressive looking brain tumour. It will also study if 5-ALA can help the surgeon achieve maximal tumour removal and discriminate between normal brain tissue and tumour.
Patients will be between 3-18 years (inclusive) and all patients will receive 5-ALA 3-6 hours prior to resection surgery.

开始日期2024-11-30

申办/合作机构

University College London

[+1]

100 项与盐酸氨酮戊酸相关的临床结果

登录后查看更多信息

100 项与盐酸氨酮戊酸相关的转化医学

登录后查看更多信息

100 项与盐酸氨酮戊酸相关的专利（医药）

登录后查看更多信息

13,422

项与盐酸氨酮戊酸相关的文献（医药）

2025-12-31·Epigenetics

Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines

Article

作者: Kaul-Ghanekar, Ruchika ; Raina, Prerna ; Ulhe, Amrita ; Chaudhary, Amol

Cervical cancer, the fourth most common cancer globally and the second most prevalent cancer among women in India, is primarily caused by Human Papilloma Virus (HPV). The association of diet with cancer etiology and prevention has been well established and nutrition has been shown to regulate cancer through modulation of epigenetic markers. Dietary fatty acids, especially omega-3, reduce the risk of cancer by preventing or reversing the progression through a variety of cellular targets, including epigenetic regulation. In this work, we have evaluated the potential of ALA (α linolenic acid), an ω-3 fatty acid, to regulate cervical cancer through epigenetic mechanisms. The effect of ALA was evaluated on the regulation of histone deacetylases1, DNA methyltransferases 1, and 3b, and global DNA methylation by ELISA. RT-PCR was utilized to assess the expression of tumor regulatory genes (hTERT, DAPK, RARβ, and CDH1) and their promoter methylation in HeLa (HPV18-positive), SiHa (HPV16-positive) and C33a (HPV-negative) cervical cancer cell lines. ALA increased DNA demethylase, HMTs, and HATs while decreasing global DNA methylation, DNMT, HDMs, and HDACs mRNA expression/activity in all cervical cancer cell lines. ALA downregulated hTERT oncogene while upregulating the mRNA expression of TSGs (Tumor Suppressor Genes) CDH1, RARβ, and DAPK in all the cell lines. ALA reduced methylation in the 5' CpG island of CDH1, RARβ, and DAPK1 promoters and reduced global DNA methylation in cervical cancer cell lines. These results suggest that ALA regulates the growth of cervical cancer cells by targeting epigenetic markers, shedding light on its potential therapeutic role in cervical cancer management.

2025-04-01·MAGNETIC RESONANCE IN MEDICINE

Imaging treatment efficacy of repeated photodynamic therapy in glioblastoma using chemical exchange transfer saturation MRI

Article

作者: Liu, Yang ; Lai, Joseph H. C. ; Chen, Zilin ; Leung, Vivian W. M. ; Huang, Jianpan ; Park, Se Weon ; Chan, Kannie W. Y. ; Hu, Charles

Abstract:

Purpose:

To observe the tumor responses during photodynamic therapy in a murine glioblastoma model using chemical exchange saturation transfer (CEST) MRI and to compare the treatment effectiveness between single photodynamic therapy (sPDT) and repeated PDT (rePDT).

Methods:

After tumor cell implantation in NSG mouse brain (n = 27), mice were subjected to four PDT sessions (rePDT), sPDT after the administration of 5‐aminolevulinic acid 6 h before each session, and a non‐PDT session (control). A 630‐nm LED light was used to effectuate PDT. After 24 h for each PDT session, T2‐weighted and CEST MRI were performed over 7 days.

Results:

We observed that rePDT resulted in a continuous suppression of tumors according to T2‐weighted images; thus, the tumor volume was the smallest among three groups on Day 7. Both CEST contrasts at 3.5 ppm (amide proton transfer, APT) and 3.5 ppm (relayed nuclear Overhauser enhancement, rNOE) in the rePDT group were significantly lower (p < 0.05) than those in the control group starting from Day 5, which corresponds to lower protein and cellularity in tumors in the rePDT group, respectively. CEST contrast decreased by 17.9% at 3.5 ppm and 11.3% at 3.5 ppm for rePDT group. This was validated by histology, where we observed moderate correlations between APT with cell proliferation (R = 0.730, p < 0.01) and cell apoptosis (R = 0.715, p < 0.05) and moderate correlation between rNOE with cellularity (R = 0.796, p < 0.01).

Conclusions:

rePDT has a better effect in tumor growth suppression when compared with sPDT, and CEST could be a robust and noninvasive mean to assess the molecular changes related to treatment efficacy.

2025-04-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Corrigendum to “Characterization and functional properties of walnut protein fibrils for enhanced bioaccessibility of CoQ10 and ALA” [International Journal of Biological Macromolecules, Volume 285 (2025), 138171]

作者: He, Xiaoyu ; Zhang, Li ; Cao, Minjie ; Mi, Jie ; Song, Yuehao ; Wang, Xingguo ; Guo, Yiwen ; Chang, Ming ; Zhu, Zhu ; Liu, Ruijie

107

项与盐酸氨酮戊酸相关的新闻（医药）

2025-02-25

·PRNewswire

Alpheus Medical Publishes Promising Early Clinical Results of Sonodynamic Therapy for the Treatment of Newly Diagnosed Glioblastomas

CHANHASSEN, Minn., Feb. 25, 2025 /PRNewswire/ -- Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today announced the publication of a study in the Journal of Neuro-Oncology showcasing its proprietary SDT treatment in three patients with newly diagnosed glioblastomas that were not candidates for gross total tumor resection. The study reported no adverse effects with an immediate positive imaging and histopathological response indicating cancer cell death, with no impact on healthy brain tissue, after a single dose of SDT. The Company shared that it expects to begin a randomized control trial in patients with newly diagnosed glioblastoma later this year. Continue Reading "The early clinical results are very encouraging for advancing treatment options in patients with newly diagnosed glioblastoma, a disease with few effective therapies," commented Walter Stummer, Professor and Director of the Department of Neurosurgery of the University Hospital Münster, Germany, and the senior author of the study. "Sonodynamic therapy's ability to selectively induce immediate tumor cell death while sparing healthy brain tissue is unprecedented. Additionally, its diffuse nature allows treatment across the entire hemisphere, including the peripheral invasive zone and beyond, a major challenge in neuro-oncology. These factors suggest that SDT could be a significant breakthrough in glioblastoma treatment." "SDT's ability to selectively induce immediate tumor cell death while sparing healthy brain tissue is unprecedented." Post this Alpheus Medical's novel SDT therapy delivers low-intensity diffuse ultrasound (LIDU™) combined with oral 5-aminolevulinic acid (5-ALA) to selectively target and destroy cancer cells across the entire brain hemisphere. This non-invasive treatment, performed without the need for imaging or sedation, offers a revolutionary new approach to cancer care in an outpatient setting. This news builds on the previously presented first-in-human positive results from the Company's Phase 1/2 trial in recurrent, high-grade glioma patients, a population with very short survival expectancy. The open-label, multicenter study demonstrated a greater than twofold increase in median overall survival and a threefold improvement in progression-free survival for patients treated with SDT, underscoring its potential as a transformative therapy for this aggressive disease. About Alpheus Medical, Inc. Alpheus Medical is a private, clinical-stage oncology company revolutionizing the treatment of solid body cancers with its pioneering sonodynamic therapy (SDT) platform that combines Low-Intensity Diffuse Ultrasound (LIDUTM) with the sensitizing agent, oral 5-aminolevulinic acid (5-ALA). The company's proprietary, non-invasive technology is designed to selectively target and destroy cancer cells in the brain while preserving healthy tissue. Alpheus Medical collaborates with global neuro-oncology leaders and receives support from Brightedge, the impact investment and innovation arm of the American Cancer Society, and the Brain Tumor Investment Fund, a subsidiary of the National Brain Tumor Society. Learn more at . SOURCE Alpheus Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果ASCO会议

2025-02-08

·国际糖尿病idiabetes

糖尿病患者是否需要补充ω-3脂肪酸？

点击“蓝字”关注我们编者按医学营养治疗(MNT)是糖尿病护理的一个重要方面，具有抗炎和抗氧化作用的ω-3脂肪酸，是营养模型中不可或缺的组成部分。随着医学研究的不断发展，ω-3脂肪酸的潜在益处逐渐被认识到，尤其在糖尿病管理中的作用也逐渐成为学术界和临床实践中的关注点。那么糖尿病患者是否需要补充ω-3脂肪酸？如果需要，又该如何补充呢？什么是ω-3脂肪酸？ ω-3脂肪酸属于多不饱和脂肪酸。不饱和脂肪酸是人体不可缺少的脂肪酸，根据双键个数，分为单不饱和脂肪酸和多不饱和脂肪酸。多不饱和脂肪酸包括亚油酸、亚麻酸、花生四烯酸（AA）等，人体不能合成亚油酸和α-亚麻酸，必须从膳食中补充。根据双键的位置及功能，又可以将多不饱和脂肪酸分为ω-6和ω-3系列。亚油酸和AA属ω-6脂肪酸系列家族成员。ω-3脂肪酸是指具有多个双键的多不饱和脂肪酸，其中最常见的三种类型为：α-亚麻酸（ALA）、二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）。ALA主要来源于植物油（如亚麻籽油、奇亚籽等），而EPA和DHA则主要来源于深海鱼类和某些海洋生物[1]。 ω-3脂肪酸对人体有多种有益作用[1]。它们有助于维持细胞膜的流动性，预防炎症，促进抗炎花生酸的产生。它们还可以减少促炎蛋白激酶、趋化因子、细胞因子和生长因子的分泌和活性。此外，它们还可以抑制黏附分子的产生并改善血管内皮细胞的功能。ω-3 脂肪酸还可以防止血小板聚集并减少肝脏中的甘油三酯合成。当代替饱和脂肪使用时，它们可以降低低密度胆固醇水平。此外，它们还可以增强葡萄糖的吸收，增加癌细胞膜的饱和度，并促进自由基的吸收，从而损害癌细胞。ω-3脂肪酸还可以通过调节下丘脑来抑制食欲，并影响脂肪组织中的基因表达。为了维持体内平衡，身体会调节脂肪因子的释放，通过产热作用增加脂肪氧化和潜在的能量消耗，激活肌肉合成代谢机制，并影响表观遗传学。这些过程对心血管疾病、糖尿病、癌症、肥胖症和神经退行性疾病等慢性和代谢疾病有影响。 ω-3脂肪酸在糖尿病管理中的作用糖尿病，尤其是T2DM，通常伴随胰岛素抵抗、慢性低度炎症和代谢紊乱等问题，近年来的研究表明，ω-3脂肪酸在糖尿病管理中可能具有潜在的益处。ω-3脂肪酸对糖尿病前期和糖尿病代谢的有益影响可归因于其抗氧化、抗炎、抗血脂、抗脂肪生成、增强胰岛素敏感性和改善胰岛素抵抗的特性。改善胰岛素敏感性胰岛素抵抗是2型糖尿病的核心病理机制之一。多项研究表明[2~3]，ω-3脂肪酸能够通过多种机制改善胰岛素敏感性。具体机制包括：1）减少脂肪沉积：ω-3脂肪酸通过促进脂肪酸氧化，减少内脏脂肪沉积，从而减轻胰岛素抵抗。2）调节脂肪酸代谢：ω-3脂肪酸可以减少游离脂肪酸的水平，而游离脂肪酸会影响胰岛素的功能。降低慢性低度炎症糖尿病患者通常伴有慢性低度炎症，这与胰岛素抵抗、糖尿病并发症（如心血管疾病、肾病）密切相关。ω-3脂肪酸因其抗炎作用被广泛研究。ω-3脂肪酸通过以下机制发挥抗炎作用[4~5]：1）抑制促炎细胞因子的分泌：ω-3脂肪酸能够抑制如肿瘤坏死因子-α（TNF-α）、白介素-6（IL-6）等促炎因子的分泌，从而减轻炎症反应。2）降低C-反应蛋白（CRP）水平：CRP是一种反映全身性炎症反应的标志物，ω-3脂肪酸能够显著降低其水平。改善心血管健康心血管疾病是糖尿病患者最常见的并发症之一，尤其是T2DM。ω-3脂肪酸具有显著的心血管保护作用，主要体现在以下几个方面：1）降低血脂水平：ω-3脂肪酸能够降低总胆固醇、低密度脂蛋白胆固醇（LDL-C）以及甘油三酯水平，从而改善血脂状态。2）改善血管功能：ω-3脂肪酸有助于改善血管内皮功能，减少血管硬化，降低动脉粥样硬化的风险。3）抗血栓作用：ω-3脂肪酸通过减少血小板聚集，降低血栓形成的风险。糖尿病患者是否需要补充ω-3脂肪酸？食物来源补充：富含ω-3脂肪酸的食物主要有深海鱼类（如三文鱼、鲭鱼、沙丁鱼等）和某些植物油（如亚麻籽油、奇亚籽油、胡桃等）。美国心脏协会（AHA）建议[6]，成年人每周应至少食用两次富含ω-3的鱼类，或者每天通过食物摄入一定量的ALA。对于不食用鱼类的糖尿病患者，可以通过植物性ω-3来源来补充，但ALA转化为EPA和DHA的效率较低，因此植物性来源可能不足以满足日常所需。 ω-3脂肪酸补充剂补充：ω-3脂肪酸制剂分为非处方产品和处方产品。非处方产品（主要为鱼油）属于膳食补充剂，无需受到药品监管部门的严格监督与管理；且非处方制剂的种类较多，剂量不等，未经过随机对照试验（RCT）研究，虽是安全的，但因不适用于治疗疾病，因而不能作为ω-3脂肪酸处方药物的替代品。2023年美国糖尿病协会（ADA）指南指出[7]，ω-3脂肪酸的补充应作为糖尿病患者饮食干预的一部分。特别是对于已有心血管疾病风险的糖尿病患者，ω-3脂肪酸能够有效预防心血管事件的发生。ADA建议，糖尿病患者应优先通过食物补充ω-3脂肪酸，必要时可以考虑使用补充剂。然而，补充ω-3脂肪酸时应注意个体差异，最好在医生的指导下进行补充。 ω-3脂肪酸补充的潜在风险：尽管ω-3脂肪酸有众多益处，但其过量补充也可能带来一些副作用，特别是对于糖尿病患者来说。高剂量的ω-3脂肪酸补充可能增加出血风险，特别是当患者正在服用抗凝药物时。此外，大剂量的鱼油补充可能导致胃肠不适、腹泻或体重增加。因此，在补充ω-3脂肪酸时，应该根据医生建议控制剂量，避免过量。结语 ω-3脂肪酸对于糖尿病患者的健康具有潜在的益处，尤其是在改善心血管健康、减轻炎症反应和提升胰岛素敏感性方面。尽管ω-3脂肪酸对糖尿病血糖控制的直接作用尚不明确，但其对降低心血管疾病风险的作用已被广泛认可。糖尿病患者在补充ω-3脂肪酸时，应该优先通过饮食来源，如深海鱼类等，必要时可以通过补充剂进行补充。同时，补充剂的使用应遵循专业医生的建议，避免过量。参考文献（上下滑动可查看） 1.ω-3脂肪酸处方药物在老年疾病中的应用专家共识（2024版）.《中华医学杂志》, 2024,104(9) : 635-649. 2.Balk, E. M., Lichtenstein, A. H., & Chung, M. (2018). ω-3 fatty acids and insulin sensitivity: A systematic review. Journal of Clinical Endocrinology & Metabolism, 103(6), 2112-2123. 3.Bays, H. (2015). ω-3 fatty acids and cardiovascular disease: A review of the current evidence. Journal of Clinical Lipidology, 9(2), 162-168. 4.He, K., Zhao, L., & Xu, G. (2020). ω-3 fatty acids supplementation and cardiovascular outcomes in type 2 diabetes: A randomized controlled trial. JAMA, 323(15), 1553-1562. 5.Vallianou, N. G., Stratigou, T., & Migdalis, I. (2017). ω-3 fatty acids in the management of type 2 diabetes mellitus. Diabetes & Metabolism, 43(3), 169-177. 6.Rimm E B, Appel L J, Chiuve S E, et al.(2018)Seafood Long-Chain n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: A Science Advisory From the American Heart Association.Circulation. 2018 Jul 3;138(1):e35-e47. doi: 10.1161/CIR.0000000000000574. Epub 2018 May 17. 7.American Diabetes Association. (2023). 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2023. Diabetes Care, 46(Supplement 1), S125-S140. https://doi-org.libproxy1.nus.edu.sg/10.2337/dc23-S009 声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《国际糖尿病》编辑部）版权声明版权属《国际糖尿病》所有。欢迎个人转发分享。其他任何媒体、网站未经授权，禁止转载。

临床结果

2025-02-05

·奇点网

《自然·衰老》：Omega-3抗衰新证！临床试验表明，每日1克omega-3可有效延缓生物年龄，坚持3年或能年轻3.8个月

*仅供医学专业人士阅读参考深海鱼油，算得上是保健品的荣光了。其富含的Omega-3脂肪酸，不仅有助于改善心血管健康、增强大脑功能和缓解炎症，还被认为具有延年益寿的潜力。过了个新年，Omega-3现身国际顶刊，带着最新证据发声：我，Omega-3，真的可以抗衰！这回使用的指标非常硬核，是衡量衰老程度的更准确、更科学指标——生物年龄，它能够反映身体实际的健康状态，而不仅仅是时间的流逝。生物年龄的增加通常伴随着多种健康问题的风险上升，如心血管疾病、糖尿病、认知衰退等。而近日发表于《自然·衰老》杂志的论文中[1]，瑞士苏黎世大学的Heike A. Bischoff-Ferrari及其同事通过分析777名老年人的DNA甲基化程度证明，坚持3年每天补充1克的Omega-3，能够将生物学衰老延缓近4个月，结合补充维生素D和多多运动的话效果更好。论文首页截图 Omega-3脂肪酸是一类人体无法自行合成的多不饱和脂肪酸，主要包括ALA、EPA和DHA，只能通过补充剂或饮食（深海鱼或亚麻籽、大豆、藻类等植物）来摄入。为防止大家乱吃一顿，Omega-3的功效被反复质疑和验证。目前统一的标准是，世界卫生组织（WHO）、美国心脏协会（AHA）等健康组织建议成年人每日摄入250-500毫克的EPA和DHA用来维持心血管健康。如果不借助补充剂、单靠饮食，吃深海鱼是捷径，而植物性Omega-3（来自亚麻籽、核桃、奇亚籽等食物的ALA）在体内转化为EPA和DHA的效率较低，因此需要更多摄入量来获得相同的效果。这次等待omaga-3的是关于抗衰功效的考核。生物年龄是衡量个体衰老程度的指标，反映了基因和生理功能的实际状态，相比传统的时间年龄能够更准确地体现遗传因素和生活因素对健康状况的综合影响。根据DNA甲基化程度，也就是看看DNA分子某些碱基附加甲基团的情况，科学家可以推算出生物年龄。在这项名为DO-HEALTH Bio-Age的研究中，研究团队采用PhenoAge、GrimAge、GrimAge2、DunedinPACE四种先进的DNA甲基化时钟，通过采集血液样本，评估777名健康且身体活跃的瑞典老年参与者的生物年龄。参与者的平均年龄为75.5岁，59%为女性。研究的主要结果显示，与补充安慰剂相比，老年人通过口服补充剂，持续3年、每天补充1克的Omega-3（330毫克EPA、660毫克DHA），在三种时钟（PhenoAge、GrimAge2、DunedinPACE）中显示出显著抗衰作用，坚持3年可减少0.16-0.32个单位，相当于生物学衰老延缓约2.9至3.8个月。除了本身的抗衰效果，如果在补充Omega-3的同时，每天再服用2000 IU的维生素D外加每周3次、每次30分钟的身体锻炼，在PhenoAge时钟上显示出显著的加成效应，坚持3年可减少0.24至0.32个单位。单独补充维生素D或者运动时，对这几种DNA甲基化时钟的改变都较为有限。用四种时钟来评估维生素D、运动、Omega-3对生物年龄的影响基于DO-HEALTH试验，研究者们对Omega-3的其它功效也进行了考察。这项DO-HEALTH试验共纳入了2157名来自5个欧洲国家（瑞士、法国、德国、葡萄牙和奥地利）年龄70岁及以上的老年人，研究结果提示，与未服用Omega-3补充剂的人相比，服用33年Omega-3补充剂可将跌倒发生率降低10%[2]、感染发生率降低13%[3]；同时补充Omega-3和维生素D再加上运动，可以将虚弱发生率降低39%[4]、侵袭性癌症患病率降低61%[5]。延缓生物学衰老这一考验，Omega-3算是通过了，与维生素D、运动相结合更锦上添花。但是重中之重的事情还是要说三遍：量不能贪！不能贪！不能贪！补充太多可能会适得其反[6]，增加心房颤动风险，通常建议每天最多补充1克Omega-3。参考文献： [1]Bischoff-Ferrari, H.A., Gängler, S., Wieczorek, M. et al. Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Nat Aging (2025). https://doi-org.libproxy1.nus.edu.sg/10.1038/s43587-024-00793-y [2]Bischoff-Ferrari, H. A. et al. Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial. JAMA 324, 1855–1868 (2020). [3]Bischoff-Ferrari, H. A. et al. Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial. Am. J. Clin. Nutr. 115, 1311–1321 (2022). [4]Gagesch, M. et al. Effects of vitamin D, omega-3 fatty acids and a home exercise program on prevention of pre-frailty in older adults: the DO-HEALTH randomized clinical trial. J. Frailty Aging 12, 71–77 (2023). [5]Bischoff-Ferrari, H. A. et al. Combined vitamin D, omega-3 fatty acids, and a simple home exercise program may reduce cancer risk among active adults aged 70 and older: a randomized clinical trial. Front. Aging 3, 852643 (2022). [6]https://www-nature-com.libproxy1.nus.edu.sg/articles/d41586-025-00355-1 本文作者丨张艾迪

临床结果临床研究

100 项与盐酸氨酮戊酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02908	盐酸氨酮戊酸	L01XD04	DB00855

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
浸润性膀胱癌	日本	SBI Pharmaceuticals Co., Ltd.	2017-09-27
多形性胶质母细胞瘤	澳大利亚	Specialised Therapeutics Glio Pty Ltd	2013-11-07
造影剂	日本	Nobelpharma Co., Ltd.	2013-03-25
基底细胞癌	欧盟	Biofrontera Bioscience GmbH	2011-12-13
基底细胞癌	冰岛	Biofrontera Bioscience GmbH	2011-12-13
基底细胞癌	列支敦士登	Biofrontera Bioscience GmbH	2011-12-13
基底细胞癌	挪威	Biofrontera Bioscience GmbH	2011-12-13
胶质瘤	欧盟	Photonamic GmbH & Co. KG	2007-09-07
胶质瘤	冰岛	Photonamic GmbH & Co. KG	2007-09-07
胶质瘤	列支敦士登	Photonamic GmbH & Co. KG	2007-09-07
胶质瘤	挪威	Photonamic GmbH & Co. KG	2007-09-07
尖锐湿疣	中国	上海复旦张江生物医药股份有限公司	2007-02-14
光化性角化病	美国	Sun Pharmaceutical Industries, Inc.	1999-12-03

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非肌层浸润性膀胱肿瘤	临床3期	中国	上海复旦张江生物医药股份有限公司	2025-01-20
卵巢上皮癌	临床3期	美国	NX Development Corp.	2024-05-30
复发性卵巢癌	临床3期	美国	NX Development Corp.	2024-05-30
乳腺癌	临床3期	美国	Sbi Alapharma Canada, Inc.	2021-04-27
恶性上皮肿瘤	临床3期	美国	Sbi Alapharma Canada, Inc.	2021-04-27
脑膜瘤	临床3期	美国	NX Development Corp.	2020-10-28
脑膜瘤	临床3期	奥地利	NX Development Corp.	2020-10-28
脑膜瘤	临床3期	德国	NX Development Corp.	2020-10-28
浅表型基底细胞癌	临床3期	美国	Biofrontera Bioscience GmbH	2018-09-25
脑恶性胶质瘤	临床3期	日本	Nobelpharma Co., Ltd.	2010-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


TMOD-04 (SNO2024)	临床1期	-	8	Sonodynamic Therapy with 5-ALA HCL Oral Solution and CV-01	憲醖壓選壓製築淵鏇範(醖齋憲觸顧範繭繭簾鑰) = 選餘鏇鬱積遞餘觸膚鹽遞窪鏇觸艱蓋願顧鑰選 (獵鏇鏇蓋鬱網積餘觸鑰 )	积极	2024-11-11
				5-ALA HCL oral solution (Control Group)	憲醖壓選壓製築淵鏇範(醖齋憲觸顧範繭繭簾鑰) = 憲淵選膚鹹鹹築憲蓋鬱遞窪鏇觸艱蓋願顧鑰選 (獵鏇鏇蓋鬱網積餘觸鑰 )
NCT01128218 (Phase 2 Sensitivity and Selectivity Study, Pubmed \| Oper Neurosurg (Hagerstown))	临床2期	复发性胶质母细胞瘤	31	High-dose 5-ALA (>40 mg/kg)	簾餘憲選齋顧顧顧艱壓(淵衊製願鏇願淵願網繭) = 膚襯糧窪願醖醖鏇製顧壓憲餘簾網蓋遞衊鹽壓 (鑰膚襯鏇鏇選膚壓構蓋 ) 更多	积极	2024-11-11
				Low/standard dose 5-ALA (<30 mg/kg)	簾餘憲選齋顧顧顧艱壓(淵衊製願鏇願淵願網繭) = 鬱醖構衊製齋衊鏇顧觸壓憲餘簾網蓋遞衊鹽壓 (鑰膚襯鏇鏇選膚壓構蓋 ) 更多
NCT03573401 (ALA-BCC-CT013, GlobeNewswire) 人工标引	临床3期	基底细胞癌	187	Ameluz®-PDT	簾鬱膚鬱簾餘鏇艱夢鹽(廠膚窪淵簾糧鑰鹹淵襯) = 繭繭繭簾窪獵鏇醖膚構糧膚鬱遞齋鹽鑰廠憲壓 (廠範製選選獵蓋觸範鹹 ) 更多	积极	2024-10-31
				Placebo-PDT	簾鬱膚鬱簾餘鏇艱夢鹽(廠膚窪淵簾糧鑰鹹淵襯) = 選淵憲鏇齋窪廠積餘積糧膚鬱遞齋鹽鑰廠憲壓 (廠範製選選獵蓋觸範鹹 ) 更多
P18.53.A (EANO2024)	N/A	胶质母细胞瘤辅助 5-aminolevulinic acid (5-ALA) positive	23	5-aminolevulinic acid (5-ALA) (No residual 5-ALA)	遞蓋願築艱淵獵構願齋(築蓋齋齋艱簾衊窪鏇顧) = 積觸構範鬱淵鏇簾醖遞壓齋壓願膚範餘夢鹹獵 (簾憲範憲願鹽廠蓋獵觸 ) 更多	不佳	2024-10-17
				5-aminolevulinic acid (5-ALA) (Focal residual 5-ALA)	遞蓋願築艱淵獵構願齋(築蓋齋齋艱簾衊窪鏇顧) = 獵鹹鏇壓製積衊遞醖襯壓齋壓願膚範餘夢鹹獵 (簾憲範憲願鹽廠蓋獵觸 ) 更多
P10.22.B (EANO2024)	N/A	胶质瘤	163	5-ALA (Fluorescent Gliomas)	夢糧選簾夢繭夢壓衊築(糧夢繭遞廠範繭鑰襯糧) = 夢鏇襯壓鑰構蓋構壓鹽餘淵衊築窪蓋鹽糧遞醖 (醖餘窪簾簾鑰鏇艱膚觸 ) 更多	积极	2024-10-17
NCT03048240 (INDYGO, Pubmed \| J Neurooncol)	N/A	胶质母细胞瘤 5-aminolevulinic acid hydrochloride (5-ALA HCl)	-	Intraoperative photodynamic therapy (PDT) with 5-aminolevulinic acid hydrochloride (5-ALA HCl)	製繭獵膚鹽築艱壓衊齋(選壓憲範餘夢製夢廠夢) = 網糧壓膚鹽網廠鑰鹹鑰壓糧蓋壓鬱築獵壓糧獵 (艱觸餘觸艱鹽鹽膚遞夢 ) 更多	积极	2024-07-01
NCT03327831 (CTgov)	临床4期	光化性角化病	30	Aminolevulinic Acid	衊糧糧獵製選鹽淵範衊(積襯鹹繭顧艱鑰構艱蓋) = 獵鏇淵壓顧憲繭鏇築憲淵繭顧艱鬱艱鑰鑰顧鑰 (顧蓋簾鹽築遞糧鏇廠壓, 顧衊廠艱製鏇醖憲繭鏇 ~ 顧艱鏇選觸膚夢窪餘鹹) 更多	-	2024-06-27
PD30-02 (AUA2024)	N/A	膀胱癌	302	Fluorescence cystoscopy using oral 5-aminolevulinic acid (ALA)	膚壓繭繭壓顧襯觸獵齋(鏇願廠遞鬱製構壓鏇衊) = 鹹構齋製鹹範鑰鑰蓋鬱構選觸淵糧遞壓積淵顧 (廠積壓簾憲鏇餘積壓製 ) 更多	不佳	2024-05-01
				5-AMINOLEVULINIC ACID (White light cystoscopy)	膚壓繭繭壓顧襯觸獵齋(鏇願廠遞鬱製構壓鏇衊) = 壓範製鬱獵顧網願願簾構選觸淵糧遞壓積淵顧 (廠積壓簾憲鏇餘積壓製 ) 更多
MP77-20 (AUA2024)	N/A	非肌层浸润性膀胱肿瘤	33	Fluorescence cystoscopy using oral 5-aminolevulinic acid (ALA)	鹹醖蓋鬱網構蓋醖憲鬱(壓廠簾選構蓋製廠遞鏇) = 製範窪願網夢艱簾衊鹹築窪範糧窪淵構顧窪觸 (膚選廠齋願網鑰襯憲鑰 ) 更多	积极	2024-05-01
				5-aminolevulinic acid (White-light endoscopy)	鹹醖蓋鬱網構蓋醖憲鬱(壓廠簾選構蓋製廠遞鏇) = 鬱醖鑰憲鹹淵糧鏇廠鏇築窪範糧窪淵構顧窪觸 (膚選廠齋願網鑰襯憲鑰 ) 更多